Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ ºÚÁÏÍø Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Approximately 4-40% of the male breast cancers have been attributed to various genetic mutations like PTEN, BRCA, AR and
CHEK2 gene. Here we present a rare association of male breast cancer with Neurofibromatosis-1 (NF-1) in a 56 year-old white
male with a history of NF-1, who discovered a mass in his right breast. Breast imaging showed a right breast mass (6.9Ã?Â?2.0 cm)
with enlarged axillary lymph nodes. Biopsy revealed invasive ductal carcinoma. He underwent neoadjuvant chemotherapy with
modified radical mastectomy. Gross examination revealed two lesions, one in the center of the breast, posterior to the nipple (2.5 cm),
other in the middle of the outer quadrants (1.5 cm). Microscopic examination revealed multifocal invasive ductal adenocarcinoma,
Nottingham Grade 3, pathological stage IIA, pT2 (m), pN0. Immunohistochemistry for estrogen (ER) and progesterone (PR) were
negative with equivocal HER2 in the smaller nodule. The larger mass in the center was ER+, PR+ with equivocal HER2. HER2 FISH
studies showed amplification in both masses. Male breast cancer is rare (<1%) of all breast carcinomas with a mean age of diagnosis
between 60-70 years. Literature search showed only 4 male patients who had NF-1 and subsequently developed breast cancer with
average age of onset of 52 years. The NF1 mutation could have predisposed these individuals to an early development of breast cancer
with high grade and advanced stages. NF-1 is associated with a negative regulation of the RAS signaling pathway, it will be intriguing
to find out if novel drugs targeting the Ras pathway can be of use in treatment of this specific subset of breast cancer. There is also
increasing evidence that depletion of NF1 protein makes the drug tamoxifen less sensitive and also leads to the resistance in human
breast cancer cell lines.
Biography
Snehal Shankar Sonawane has completed her Medical School at Government Medical College Miraj and has done Diplomate of National Board in Pathology from RCSM Government Medical College Kolhapur. She is presently working as Pathology Resident Physician at University of Illinois at Chicago. Her research work is in area of ‘Dry eye disease’ and is published in reputed journals.